Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLDEN: Sefaxersen in Geographic Atrophy Secondary to AMD
NCT03815825Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Apr 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in geographic atrophy (GA) comparing Sefaxersen with Placebo (2 arms). Primary endpoint: Rate of Change from Baseline in the Geographic Atrophy (GA) Area at 49 weeks. Started Mar 2019; status: completed.
02
Drugs
sefaxersen
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03815825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815825.